GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » Cash Ratio

Viva Biotech Holdings (HKSE:01873) Cash Ratio : 0.68 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Viva Biotech Holdings's Cash Ratio for the quarter that ended in Dec. 2023 was 0.68.

Viva Biotech Holdings has a Cash Ratio of 0.68. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Viva Biotech Holdings's Cash Ratio or its related term are showing as below:

HKSE:01873' s Cash Ratio Range Over the Past 10 Years
Min: 0.25   Med: 0.88   Max: 12.8
Current: 0.68

During the past 8 years, Viva Biotech Holdings's highest Cash Ratio was 12.80. The lowest was 0.25. And the median was 0.88.

HKSE:01873's Cash Ratio is ranked worse than
77.75% of 1474 companies
in the Biotechnology industry
Industry Median: 2.675 vs HKSE:01873: 0.68

Viva Biotech Holdings Cash Ratio Historical Data

The historical data trend for Viva Biotech Holdings's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings Cash Ratio Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial 12.80 3.21 0.86 0.25 0.68

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.25 0.34 0.68 -

Competitive Comparison of Viva Biotech Holdings's Cash Ratio

For the Biotechnology subindustry, Viva Biotech Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viva Biotech Holdings's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's Cash Ratio falls into.



Viva Biotech Holdings Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Viva Biotech Holdings's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1133.507/1678.052
=0.68

Viva Biotech Holdings's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1133.507/1678.052
=0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viva Biotech Holdings  (HKSE:01873) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Viva Biotech Holdings Cash Ratio Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Viva Biotech Holdings Business Description

Traded in Other Exchanges
Address
735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation (CDMO) and commercialisation services segment include contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates, and formulations. Geographically, the company generates a majority of its revenue from the United States of America, and the rest from the European Union, Chinese Mainland, Africa, and other regions.
Executives
Mao Chen Cheney 2101 Beneficial owner
Wu John Jiong 2201 Interest of corporation controlled by you
Fenghe Harvest Ltd 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Mao Jun 2501 Other
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Zhou Min 2202 Interest of your spouse
Intertrust (singapore) Ltd. 2301 Trustee
Z&m International Holdings Limited 2201 Interest of corporation controlled by you
Zhang And Sons Limited 2101 Beneficial owner

Viva Biotech Holdings Headlines

No Headlines